RxDoctor Payments Data

Darryn Appleton, MD

Interventional Cardiology · Richmond, VANPI 1740497007

Payments from drug & device makers

$6,622in general payments, 2019–2025

Across 184 payments — averaging $35.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$1K
  • Abbott$819
  • Medtronic$553
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$433
  • Novartis$415
  • Arineta, Inc$326
  • plus $3K from 37 others

What the payments were for

  • Travel & lodging$91914%
  • Food & beverage$5,68386%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,622 in reported general payments places this provider in the 50th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$976,841
Medicare patients
1,546
Services billed
32,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban414$340,025
XareltoRivaroxaban192$161,617
JardianceEmpagliflozin62$51,151
EntrestoSacubitril/Valsartan51$40,202
Repatha SureclickEvolocumab56$38,064
MultaqDronedarone Hcl20$28,119
FarxigaDapagliflozin Propanediol25$13,407
VascepaIcosapent Ethyl22$10,266
NexletolBempedoic Acid11$5,942
Metoprolol Succinate454$4,992
Atorvastatin Calcium344$3,312
Nebivolol Hcl43$2,895
Ezetimibe97$2,551
Rosuvastatin Calcium209$2,417
Amlodipine Besylate401$2,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$204$340,025414 claims
Johnson & JohnsonXarelto$91$161,617192 claims
Boehringer IngelheimJardiance$123$51,15162 claims
NovartisEntresto$415$40,20251 claims
Sanofi-aventis U.S. LLCMultaq$40$28,11920 claims
AstraZenecaFarxiga$54$13,40725 claims
Esperion Therapeutics, Inc.Nexletol$19$5,94211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →